BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Time to Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) shares gapped up before the market opened on Wednesday . The stock had previously closed at $15.41, but opened at $16.14. BioAge Labs shares last traded at $15.9220, with a volume of 409,767 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup lifted their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

The company has a fifty day moving average of $10.50. The company has a market cap of $547.11 million, a PE ratio of -10.04 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insiders Place Their Bets

In other BioAge Labs news, insider Paul D. Rubin sold 18,000 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 20.82% of the stock is currently owned by insiders.

Institutional Trading of BioAge Labs

Several institutional investors and hedge funds have recently made changes to their positions in BIOA. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of BioAge Labs during the second quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs during the third quarter worth about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in BioAge Labs in the 2nd quarter valued at about $57,000. Finally, Intech Investment Management LLC acquired a new stake in BioAge Labs during the 2nd quarter worth approximately $60,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.